Literature DB >> 2563787

Noradrenergic activity and silent ischaemia in hypertensive patients with stable angina: effect of metoprolol.

D D Lee1, S Kimura, V DeQuattro.   

Abstract

30 patients (10 normotensive, 20 hypertensive) with stable angina and positive treadmill exercise tests entered a double-blind, placebo-controlled crossover trial of metoprolol, 100 mg twice daily. At the end of each treatment phase, blood pressure was monitored for 24 h and Holter and real-time electrocardiographic (ECG) monitoring were carried out and an activity diary kept for 48 h. Blood samples for catecholamine measurement were taken after 30 min supine, 60 min standing, and at the first silent ischaemic event, triggered by the real-time ECG monitor, by means of an ambulatory blood withdrawal pump. Metoprolol lowered blood pressure and heart rate in both normotensive and hypertensive subjects, and reduced the frequency and duration of silent ischaemic episodes in hypertensive subjects. Plasma noradrenaline measured during silent ischaemia while the patients were resting was significantly higher than the control supine level without ischaemia. These findings suggest that noradrenergic hyperactivity may have a role in coronary vasoconstriction and that treatment which neutralizes sympathetic tone may be especially beneficial in treatment of silent ischaemia in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2563787     DOI: 10.1016/s0140-6736(89)90002-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  2 in total

1.  Impaired beta-adrenoceptor mediated venodilation in patients with diabetes mellitus.

Authors:  K Harada; M Ohmori; Y Kitoh; K Sugimoto; A Fujimura
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 2.  Adverse effects and drug interactions associated with local and regional anaesthesia.

Authors:  M Naguib; M M Magboul; A H Samarkandi; M Attia
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.